Purpose of review Since the discovery of B-Raf proto-oncogene (BRAF) V600E mutations in histiocytic neoplasms, diverse kinase alterations have been uncovered in BRAF V600E-wildtype histiocytoses. The purpose of this review is to outline recent molecular advances in histiocytic neoplasms and discuss their impact on the pathogenesis and treatment of these disorders.
INTRODUCTION
Histiocytic disorders represent a class of diseases with heterogeneous clinical courses and prognoses. They encompass disorders, including Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), Rosai-Dorfman disease (RDD), juvenile xanthogranuloma (JXG), histiocytic sarcoma, and indeterminate cell histiocytosis (ICH). All of these conditions are believed to share a common pathologic characteristic: the accumulation and infiltration of macrophages, monocytes, dendritic cells, interdigitating reticulum cells, or Langerhans cells in the affected tissues. The pathophysiology of these diseases has long been obscure, and it was previously unclear as to whether or not they represented autoimmune or clonal, neoplastic disorders [1, 2] . However, starting 6 years ago, a series of recurrent activating mutations involving the mitogenactivated protein kinase (MAPK) and phosphoinositide 3-kinases (PI3K)-Akt murine thymoma (AKT) pathways ( Fig. 1) have been discovered in a large Currently, histiocytic neoplasms are divided into LCH and non-Langerhans cell histiocytoses (non-LCH). LCH is the most common histiocytic neoplasm and most commonly occurs in children. LCH is found in five out of 1 million children, which is a similar frequency to acute myeloid leukemia and Hodgkin lymphoma in children [3] . In 2008, the WHO defined LCH as a 'clonal neoplastic proliferation of Langerhans-type cells that express CD1a, langerin, and S100 protein, and shows Birbeck granules by ultrastructural examination' [1] . LCH originally derived its name because of the fact the Birbeck granule was identified in mononuclear phagocytic cells of LCH lesions. As the Birbeck granule had only been seen in epidermal Langerhans cells previously, LCH was historically thought to arise from epidermal Langerhans cells [3, 4] . However, recent evidence suggests that LCH is actually derived from myeloid precursor cells bearing somatic mutations in MAPK pathway members. Expression profiling studies of the purified CD207 þ dendritic cells from human LCH neoplasms demonstrate a significant transcriptional overlap with immature myeloid dendritic cell precursors, whereas there is only minimal overlap with the expression profiles of human Langerhans cells [5] . Additionally, B-Raf proto-oncogene (BRAF) V600E mutations were identified in CD11c þ myeloid dendritic cell precursors and CD14 þ monocytes in systemic LCH, whereas BRAF V600E mutations were not present in the peripheral blood of patients with multifocal-tissue-restricted or single-lesion LCH. Furthermore, BRAF V600E mutations were identified in CD34 þ hematopoietic progenitor cells in several systemic LCH patients. Moreover, enforced BRAF V600E expression in mouse Cd11c þ cells results in a phenotype resembling systemic LCH, whereas enforced BRAF V600E expression in more differentiated, langerin þ dendritic cells in mice resembled multifocal-tissue-restricted or singlelesion LCH. These data led to the proposal of the 'misguided myeloid dendritic cell model of LCH pathogenesis' where the clinical severity and distribution of the LCH lesion(s) are defined by the cellular stage of myeloid differentiation during which the somatic BRAF V600E or other activating kinase mutation arises and results in pathological extracellular signal-regulated kinases (ERK) activation [3] . Further work will be needed to verify these results by attempting to understand the selfrenewal potential of CD34 þ cells bearing the BRAF V600E mutation in LCH patients and to clarify in which exact cell type within the CD34 þ compartment the BRAF V600E mutations occur within LCH.
The non-LCH are a heterogeneous group of disorders defined by the accumulation of histiocytes believed to be of monocytic/macrophage origin that do not meet the diagnostic criteria for LCH or hemophagocytic lymphohistiocytosis [1, 6, 7] . Non-LCH histiocytes are immunoreactive for CD68, CD163, factor XIIIa, and CD14 but negative for CD1a and CD207 (langerin). Some non-LCH express S100, whereas others do not. The non-LCH consist of ECD, JXG, RDD, histiocytic sarcoma, ICH, and others [1,6,7,8 & ]. Currently, whether or not non-LCH neoplasms share a similar or different cell-of-origin than LCH is unknown and will need to be an active area of research.
SOMATIC MUTATIONS OF GENES IN THE MAP KINASE AND PHOSPHOINOSITIDE 3-KINASES-AKT SIGNALING PATHWAYS IN HISTIOCYTOSES
Despite the distinct clinical and histological characteristics of many of the histiocytoses as defined by the WHO, molecular characterization of these disorders
KEY POINTS
Recurrent somatic mutations in LCH and non-LCH have refined our understanding of these enigmatic disorders as clonal, myeloid neoplasms driven by constitutive MAPK signaling.
Activating kinase mutations in BRAF, ARAF, MAP2K1, N/K/HRAS, and PIK3CA have now been described in LCH and non-LCH histiocytic neoplasms because of the implementation of next-generation sequencing technologies.
Kinase fusions involving BRAF, ALK, NTRK1, and ETV3-NCOA2 have been discovered in non-LCH histiocytic neoplasms.
Significant clinical responses to RAF inhibitors have been documented in adult and pediatric patients with BRAF V600E-mutated LCH and non-LCH marked by a prolonged durability when compared with BRAF inhibition in more common BRAF V600E-mutated malignancies.
MAP2K1 and ARAF-mutant histiocytosis patients have been reported to have clinical responses to MEK inhibition and sorafenib, respectively.
Molecular advancements in histiocytic neoplasms Durham et al. has identified molecular alterations, which are recurrent across histological subtypes. The plethora of recurrent genetic alterations recently discovered across histiocytoses encompass somatic kinase alterations affecting members of the canonical MAPK and/or PI3K-AKT signaling pathways ( Fig. 1 ). These genetic alterations are detailed below.
B-RAF PROTO-ONCOGENE
BRAF encodes the BRAF serine/threonine protein kinase that belongs to the raf family of serine/threonine kinases. The rapidly accelerated fibrosarcoma (RAF) family includes the A-Raf proto-oncogene (ARAF), BRAF, and C-Raf proto-oncogene (CRAF) kinases, which transduce mitogenic signals from the cell membrane to the nucleus and regulate the MEK-ERK signaling cascade of the MAPK pathway. BRAF mutations were first described in histiocytic neoplasms in 2010 when recurrent BRAF V600E mutations were discovered in 57% of LCH [9,10] ( Fig. 2a ). This was followed by the discovery of BRAF V600E mutations in 54% of ECD patients [11] , 62.5% of histiocytic sarcoma [12] , and in a proportion of patients deemed to have ICH [13] . These findings provided strong evidence that these disorders are clonal neoplastic conditions driven by constitutive MAPK signaling [11] . In contrast to recurrent BRAF V600E mutations, other mutations in BRAF have been found only rarely in histiocytoses. These include BRAF V600D in LCH [10, 14] , BRAF F595L in histiocytic sarcoma [15] , and BRAF V600insDLAT in LCH [16] (Fig. 2a ; Supplementary Table 1 , http://links.lww.com/COH/A13).
A-RAF PROTO-ONCOGENE
The knowledge that BRAF V600E-wildtype histiocytoses consistently showed overexpression of phospho-mitogen-activated protein kinase kinase and phospho-ERK in pathological histiocytes [9,17 ,17 & ,18,21] . MAP2K1 mutations are also present in non-LCH and occur in 14% of ECD and 27% of BRAF V600E-wildtype JXG cases [8 & ]. Based on the above studies, it appears that MAP2K1 mutations in histiocytoses cluster in the N-terminal negative regulatory domain encoded by exon 2 and the N-terminal catalytic core of the kinase domain encoded by exon 3 (Fig. 2b . Some of these MAP2K1 mutations have been biochemically characterized as activating; however, several need to be evaluated functionally. Furthermore, these MAP2K1 mutations need to be systematically evaluated for their response to diverse MEK inhibitors.
MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 1
Through performing whole exome sequencing on LCH neoplasms, Nelson et al. also discovered two somatic mutations in mitogen-activated protein kinase kinase kinase 1 (MAP3K1), which encodes an enzyme with both E3 ubiquitin ligase activity as well as serine/threonine kinase activity. MAP3K1 can phosphorylate MEK1 of the ERK MAPK cascade or MAP2K4 in the c-Jun N-terminal kinase MAPK cascade. However, the mutations identified in MAP3K1 in LCH were frameshift mutations (MAP3K1 T799fs and MAP3K1 L1481fs), with MAP3K1 L1481fs occurring in the kinase domain. These mutations are, therefore, presumed to result in loss-of-function ( Fig. 2b ; Supplementary Table 1 , http://links.lww.com/COH/A13) [10, 21] , and the role of these MAP3K1 mutations in LCH and how they might promote neoplastic growth is currently unknown [10] .
RAS ISOFORMS
The RAS isoforms include NRAS, Kirsten rat sarcoma viral oncogene homolog (KRAS), and Harvey rat sarcoma viral oncogene homolog (HRAS), which encode small GTPases that regulate the MAPK and PI3K-AKT signaling pathways. As with other hematological malignancies, recurrent mutations in N/KRAS but not in HRAS have been found in systemic histiocytoses. This includes NRAS mutations in 3-7% of ECD [8 & ,22,23] and NRAS and KRAS mutations in 18% of JXG patients, respectively (Fig. 2c ). However, RAS mutations frequently coexist with activating ARAF mutations in JXG ( Supplementary Figure 1 , http://links. lww.com/COH/A13), as discussed above [8 & ]. Similarly, NRAS and KRAS mutations are present in 12.5% and 25% of RDD patients, respectively [8 & ]. In contrast to non-LCH, rare RAS mutations have been reported in LCH patients in the setting of concomitant juvenile myelomonocytic leukemia [24] and have not been reported in patients with LCH alone. The sole exception to the lack of HRAS mutations in histiocytosis has been the report of an HRAS mutation in histiocytic sarcoma ( Fig. 2c ; Supplementary Table 1 , http://links. lww.com/COH/A13) with a concomitant BRAF F595L mutation [15] ( Supplementary Figure 1 , http://links.lww.com/COH/A13).
PHOSPHOINOSITIDE 3-KINASES ISOFORMS
The PI3K isoforms include phosphatidylinositol-4,5-bisphosphate 3 kinase, catalytic subunit a (PIK3CA) and phosphatidylinositol-4,5-bisphosphate 3 kinase, catalytic subunit d. These genes encode subunits of the PI3K, which belong to a family of lipid kinases that play a role in a diverse range of cellular functions that include proliferation and survival and are part of the PI3K-AKT signaling pathway. Consistent with the potential activation of the PI3K-AKT signaling pathway downstream of RAS mutations in non-LCH, PIK3CA mutations have been described in 17% of BRAF V600E-wildtype ECD [8 & ]. These mutations cluster in the a-helical and kinase domains of PIK3CA [8 & ,22] . Consistent with the rarity of RAS mutations in LCH, activating mutations in PIK3CA have only been identified in 1.2% of LCH patients [10, 25] . In addition to PIK3CA mutations, rare phosphatidylinositol-4,5-bisphosphate 3 kinase, catalytic subunit d mutations have been identified in JXG (Fig. 2d) [18] . The expression of PI3K isoforms and the role of constitutive PI3K-AKT signaling needs to be further evaluated in the pathogenesis of the histiocytoses.
OTHER MUTATIONS IN GENES INFLUENCING THE MAP KINASE AND PHOSPHOINOSITIDE 3-KINASES-AKT SIGNALING PATHWAYS
Other potentially relevant mutations identified in LCH [18] based on whole exome sequencing include nonrecurrent mutations in PICK1, an adaptor protein that organizes the subcellular localization of a variety of membrane proteins, and PIK3R2, a regulatory component of PI3K. Although these proteins are not directly in the MAPK cascade, they could affect ERK activation. A nonrecurrent mutation in ERBB3, a member of the epidermal growth factor receptor family of receptor tyrosine kinases, has also been reported in LCH [10, 18] ; however, it is not clear if ERBB3 is even expressed in histiocytes.
GENE FUSIONS INFLUENCING THE MAP KINASE SIGNALING PATHWAY IN HISTIOCYTOSES
In addition to somatic mutations, structural alterations and gene fusions represent important somatic alterations driving the pathogenesis of common cancers. However, no gene fusions had been uncovered in the histiocytic neoplasms until 2015 when two studies described gene fusions in BRAF V600E-wildtype, non-LCH neoplasms [8 & ,26 && ]. The activating or recurrent gene fusions found in the histiocytoses to date are described below.
B-RAF PROTO-ONCOGENE FUSIONS
In addition to BRAF mutations, fusions involving BRAF have been identified in non-LCH. These include an RNF11-BRAF fusion in JXG and a CLIP2-BRAF fusion in a patient with a non-LCH resembling histiocytic sarcoma. Both fusions were found using RNA-seq and confirmed by reverse transcription-PCR followed by Sanger sequencing and interphase fluorescence in situ hybridization [8 & ]. In both cases, exons 11-18 of BRAF were involved in the fusion, leading to loss of the N-terminal regulatory, RAS-binding domain of BRAF with placement of the intact BRAF kinase domain under the aberrant regulation of another promoter ( Fig. 2e ). It is not clear what role, if any, the N-terminal fusion partner to BRAF may play in these cases.
ANAPLASTIC LYMPHOMA RECEPTOR TYROSINE KINASE FUSIONS
In addition to BRAF fusions, two fusions involving anaplastic lymphoma receptor tyrosine kinase (ALK) have been described in ECD [both kinesin family member 5B (KIF5B)-ALK]. In both cases, the N-terminal coiled-coil domain of KIF5B was fused to the intact kinase domain of ALK resulting in inappropriate expression and constitutive activation of ALK (Fig. 2f) [8 & ]. KIF5B serves as a microtubule-dependent motor involved in the normal distribution of mitochondria and lysosomes, whereas ALK encodes a neuronal orphan receptor tyrosine kinase whose expression is normally limited to the nervous system. KIF5B-ALK fusions, therefore, result in inappropriate ALK expression and constitutive activation of the MAPK and PI3K-AKT pathways within histiocytes. The KIF5B-ALK fusions have similar configurations to previously described KIF5B-ALK fusions in nonsmall-cell lung cancer [27] and are functionally activating kinase fusions that show sensitivity to ALK inhibition in vitro [8 & ].
NEUROTROPHIC TYROSINE KINASE RECEPTOR FUSIONS
Thus far, fusion of a single neurotrophic tyrosine kinase member [neurotrophic tyrosine kinase, receptor type 1 (NTRK1)] has been described in a case of ECD. This alteration was confirmed to lead to fusion of the N-terminal coiled-coil domain of Lamin A/C (LMNA) to the intact kinase domain of NTRK1 resulting in inappropriate expression and constitutive activation of NTRK1 (Fig. 2g) [8 & ]. LMNA encodes lamins, which are components of the nuclear lamina, a fibrous layer on the inner nuclear membrane that provides a framework for the nuclear envelope. NTRK1 encodes the TrkA receptor tyrosine kinase, which is a membranebound receptor that phosphorylates itself and members of the MAPK pathway leading to cellular proliferation and differentiation. Similar to ALK, expression of NTRK1 is normally restricted to the nervous system, but LMNA-NTRK1 fusions result in inappropriate expression and constitutive activation of MAPK and PI3K-AKT pathways within histiocytes. The LMNA-NTRK1 fusion has a similar configuration to previously described LMNA-NTRK1 fusions in spitzoid neoplasms [28] .
ETS VARIANT 3-NUCLEAR RECEPTOR COACTIVATOR 2 FUSIONS
In addition to activating kinase fusions, recurrent Ets variant 3-nuclear receptor coactivator 2 fusions (ETV3-NCOA2) fusions have now been described in ICH [26 && ]. This fusion juxtaposes the N-terminal ETS domain of ETV3, a winged helix-turn-helix DNA-binding domain [26 && ,29,30] , to the C-terminal transcriptional activation domains transcriptional activation domain 1 (AD1), CBP/p300 interaction domain (CID), and transcriptional activation domain 2 (AD2) of NCOA2 (Fig. 2h ). This configuration is consistent with previously described NCOA2 fusions in cancer [26 && ,29,31-34] . Previous studies of NCOA2 fusions have demonstrated that the AD1 and CID domains are required for transformation of NCOA2 fusion proteins [29, 32, 34] . The involvement of the same NCOA2 C-terminal domains and the evidence that the AD1 and CID domains are necessary for NCOA2 fusion protein transformation supports a model where the NCOA2 C-terminal transcriptional activation domains are aberrantly targeted by the DNA-binding domain provided by an N-terminal fusion partner [26 && ,29,31-34] . It is not yet clear how the ETV3-NCOA2 fusion relates to the persistent MAPK activation known to be present in these ICH cases. Further functional characterization of the ETV3-NCOA2 fusion in the pathogenesis of histiocytic neoplasms is, therefore, needed.
ROLE OF MOLECULARLY TARGETED THERAPY IN THE HISTIOCYTIC NEOPLASMS
The initial discovery of the BRAF V600E mutation in 50% of patients with LCH [9,8 & ] and ECD [11] and the other molecular advances summarized in this review ( Fig. 3 ; Supplementary Table 1 , http:// links.lww.com/COH/A13) have led to the advent of clinical trials of targeted molecular therapeutics in these orphan hematopoietic neoplasms [8 & ] ( Fig. 3 ; Supplementary Table 2 , http://links.lww.com/COH/ A13) [35] . The outcome of reported trials and case series of histiocytosis patients treated with molecularly targeted therapies are described below.
RAF INHIBITORS
Thus far, there have been two major studies of the RAF inhibitor vemurafenib in BRAF V600Emutant histiocytoses. These include a case series of eight adult patients with severe, treatment refractory, BRAF V600E-mutated ECD or ECD/LCH hybrid disease [36 & ] and a phase II clinical trial with 18 adults with BRAF V600-mutant ECD or LCH [37 && ]. In the study by Haroche et al. [36 & ], all patients had a significant and sustained clinical response to vemurafenib as measured by PET scanning during a 6-16-month follow-up period with a mean follow-up period of 10.5 months. In the study by Hyman et al., 14/18 patients were evaluated, and there was a 43% response rate with 86% of patients (12 of 14) showing disease regression. All patients had improvement in disease-related symptoms. There was a median treatment duration of 5.9 months (0.6-18.6 months) with no ECD or LCH patients experiencing progression, while on treatment. The 12-month progression-free survival rate was 91% with a 100% overall survival for this study cohort. These data suggest that BRAF inhibition may have a clinically significant effect on the natural history of ECD and LCH [37 && ]. In contrast to the case series and clinical trial in adults, there is only a single report of a child with histiocytosis treated with vemurafenib. In this case, an 8 month old with BRAF V600E-mutated, high-risk LCH, whose disease failed to respond to multiple rounds of prior therapy, experienced dramatic clinical efficacy to vemurafenib with a sustained response during the 10-month followup period [ Given the frequency of ARAF mutations in histiocytoses, several studies have investigated therapies to target these alterations. Given a prior report of a patient with ARAF S214C-mutant nonsmall-cell lung cancer who had a dramatic response to single-agent sorafenib, we treated one ARAF S214A-mutated refractory ECD patient with sorafenib with remarkable results [8 & ]. This patient experienced regression of lesions in the retina and cavernous sinuses with a more than 50% decrease in ARAF S214A-mutant DNA in the plasma cell-free DNA after 12 weeks of sorafenib. Sorafenib is a multikinase inhibitor that inhibits all three Raf isoforms (BRAF, CRAF, and ARAF), in addition to inhibiting a host of additional kinases (including vascular endothelial growth factor receptor 1, 2, and 3, c-Kit, Flt-3, Ret proto-oncogene, and plateletderived growth factor receptor b). The clinical activity of sorafenib is thought to be because of its capacity to inhibit multiple kinases that are part of ubiquitous signaling pathways dysregulated in neoplastic disease [41] . However, preclinical studies are needed to evaluate the responsiveness of sorafenib and other RAF inhibitors to different ARAF mutations in the histiocytic neoplasms, and clinical studies on larger series of ARAF-mutated, histiocytosis patients are warranted.
MEK INHIBITORS
At present, there has been a single report of the clinical use of MEK inhibitors in MAP2K1-mutated, histiocytosis patients [8 & ]. We treated two non-LCH patients with MAP2K1 K57N and MAP2K1 Q56P mutations with trametinib and cobimetinib, respectively. Both patients experienced dramatic radiologic improvements, as well as clinical improvements, and both have been sustained for nearly 6 months. These encouraging results will need to be followed with preclinical studies to evaluate MEK inhibitor responsiveness of different MAP2K1 mutations in the histiocytic neoplasms, as well as clinical studies on cohorts of MAP2K1mutated, histiocytosis patients.
CONCLUSION
Since BRAF V600E mutations were first described in LCH, there have been tremendous molecular advances in our understanding of histiocytic neoplasms. These discoveries have directly resulted in wider use of RAF inhibitors for the treatment of BRAF V600E-mutant histiocytoses and indicate the importance of comprehensive molecular analysis in routine clinical practice. It will now be important to determine how relevant the mutations in these kinases are to histiocytic disorders such as RDD and histiocytic sarcoma, which have been less systematically studied to date. Moreover, it will be important to determine the clonal composition of histiocytoses using studies of purified lesional histiocytes and surrounding cells from histiocyte tissue biopsies. In addition, currently, the therapeutic relevance of activating ARAF, RAS, and MAP2K1 mutations, as well as activating fusions in BRAF, ALK, and NTRK1 in the histiocytoses remains to be systematically studied in clinical trial settings. Given the relative rarity of these conditions, the wider use of histology-independent clinical trials of molecularly targeted therapeutics ('basket trials') will hopeful allow inclusion of histiocytosis patients.
